Plasma proteome-based test for first-line treatment selection in metastatic non-small cell lung cancer
Purpose - Current guidelines for the management of metastatic non-small cell lung cancer (NSCLC) without driver mutations recommend checkpoint immunotherapy with PD-1/PD-L1 inhibitors, either alone or in combination with chemotherapy. This approach fails to account for individual patient variability...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2024
|
| In: |
JCO precision oncology
Year: 2024, Heft: 8, Pages: 1-12 |
| ISSN: | 2473-4284 |
| DOI: | 10.1200/PO.23.00555 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1200/PO.23.00555 Verlag, kostenfrei, Volltext: https://ascopubs.org/doi/10.1200/PO.23.00555 
|
| Verfasserangaben: | Petros Christopoulos, MD, PhD; Michal Harel, PhD; Kimberly McGregor, MD; Yehuda Brody, PhD; Igor Puzanov, MD; Jair Bar, MD, PhD; Yehonatan Elon, PhD; Itamar Sela, PhD; Ben Yellin, PhD; Coren Lahav, MSc; Shani Raveh, PhD; Anat Reiner-Benaim, PhD; Niels Reinmuth, MD; Hovav Nechushtan, MD; David Farrugia, MD; Ernesto Bustinza-Linares, MD; Yanyan Lou, MD; Raya Leibowitz, MD, PhD; Iris Kamer, PhD; Alona Zer Kuch, MD; Mor Moskovitz, MD; Adva Levy-Barda, PhD; Ina Koch, PhD; Michal Lotem, MD; Rivka Katzenelson, MD; Abed Agbarya, MD; Gillian Price, MD; Helen Cheley, RN; Mahmoud Abu-Amna, MD; Tom Geldart, MD; Maya Gottfried, MD; Ella Tepper, MD; Andreas Polychronis, MD; Ido Wolf, MD; Adam P. Dicker, MD, PhD; David P. Carbone, MD; and David R. Gandara, MD |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1929404174 | ||
| 003 | DE-627 | ||
| 005 | 20250701085634.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250701s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/PO.23.00555 |2 doi | |
| 035 | |a (DE-627)1929404174 | ||
| 035 | |a (DE-599)KXP1929404174 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Christopoulos, Petros |d 1977- |e VerfasserIn |0 (DE-588)138659702 |0 (DE-627)604886756 |0 (DE-576)308488067 |4 aut | |
| 245 | 1 | 0 | |a Plasma proteome-based test for first-line treatment selection in metastatic non-small cell lung cancer |c Petros Christopoulos, MD, PhD; Michal Harel, PhD; Kimberly McGregor, MD; Yehuda Brody, PhD; Igor Puzanov, MD; Jair Bar, MD, PhD; Yehonatan Elon, PhD; Itamar Sela, PhD; Ben Yellin, PhD; Coren Lahav, MSc; Shani Raveh, PhD; Anat Reiner-Benaim, PhD; Niels Reinmuth, MD; Hovav Nechushtan, MD; David Farrugia, MD; Ernesto Bustinza-Linares, MD; Yanyan Lou, MD; Raya Leibowitz, MD, PhD; Iris Kamer, PhD; Alona Zer Kuch, MD; Mor Moskovitz, MD; Adva Levy-Barda, PhD; Ina Koch, PhD; Michal Lotem, MD; Rivka Katzenelson, MD; Abed Agbarya, MD; Gillian Price, MD; Helen Cheley, RN; Mahmoud Abu-Amna, MD; Tom Geldart, MD; Maya Gottfried, MD; Ella Tepper, MD; Andreas Polychronis, MD; Ido Wolf, MD; Adam P. Dicker, MD, PhD; David P. Carbone, MD; and David R. Gandara, MD |
| 264 | 1 | |c December 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht am 21. März 2024 | ||
| 500 | |a Gesehen am 01.07.2025 | ||
| 520 | |a Purpose - Current guidelines for the management of metastatic non-small cell lung cancer (NSCLC) without driver mutations recommend checkpoint immunotherapy with PD-1/PD-L1 inhibitors, either alone or in combination with chemotherapy. This approach fails to account for individual patient variability and host immune factors and often results in less-than-ideal outcomes. To address the limitations of the current guidelines, we developed and subsequently blindly validated a machine learning algorithm using pretreatment plasma proteomic profiles for personalized treatment decisions. - Patients and Methods - We conducted a multicenter observational trial (ClinicalTrials.gov identifier: NCT04056247) of patients undergoing PD-1/PD-L1 inhibitor-based therapy (n = 540) and an additional patient cohort receiving chemotherapy (n = 85) who consented to pretreatment plasma and clinical data collection. Plasma proteome profiling was performed using SomaScan Assay v4.1. - Results - Our test demonstrates a strong association between model output and clinical benefit (CB) from PD-1/PD-L1 inhibitor-based treatments, evidenced by high concordance between predicted and observed CB (R2 = 0.98, P < .001). The test categorizes patients as either PROphet-positive or PROphet-negative and further stratifies patient outcomes beyond PD-L1 expression levels. The test successfully differentiates between PROphet-negative patients exhibiting high tumor PD-L1 levels (≥50%) who have enhanced overall survival when treated with a combination of immunotherapy and chemotherapy compared with immunotherapy alone (hazard ratio [HR], 0.23 [95% CI, 0.1 to 0.51], P = .0003). By contrast, PROphet-positive patients show comparable outcomes when treated with immunotherapy alone or in combination with chemotherapy (HR, 0.78 [95% CI, 0.42 to 1.44], P = .424). - Conclusion - Plasma proteome-based testing of individual patients, in combination with standard PD-L1 testing, distinguishes patient subsets with distinct differences in outcomes from PD-1/PD-L1 inhibitor-based therapies. These data suggest that this approach can improve the precision of first-line treatment for metastatic NSCLC. | ||
| 700 | 1 | |a Harel, Michal |e VerfasserIn |4 aut | |
| 700 | 1 | |a McGregor, Kimberly |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brody, Yehuda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Puzanov, Igor |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bar, Jair |e VerfasserIn |4 aut | |
| 700 | 1 | |a Elon, Yehonatan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sela, Itamar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yellin, Ben |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lahav, Coren |e VerfasserIn |4 aut | |
| 700 | 1 | |a Raveh, Shani |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reiner-Benaim, Anat |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reinmuth, Niels |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nechushtan, Hovav |e VerfasserIn |4 aut | |
| 700 | 1 | |a Farrugia, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bustinza-Linares, Ernesto |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lou, Yanyan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leibowitz, Raya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kamer, Iris |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zer Kuch, Alona |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moskovitz, Mor |e VerfasserIn |4 aut | |
| 700 | 1 | |a Levy-Barda, Adva |e VerfasserIn |4 aut | |
| 700 | 1 | |a Koch, Ina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lotem, Michal |e VerfasserIn |4 aut | |
| 700 | 1 | |a Katzenelson, Rivka |e VerfasserIn |4 aut | |
| 700 | 1 | |a Agbarya, Abed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Price, Gillian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cheley, Helen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Abu-Amna, Mahmoud |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geldart, Tom |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gottfried, Maya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tepper, Ella |e VerfasserIn |4 aut | |
| 700 | 1 | |a Polychronis, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wolf, Ido |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dicker, Adam P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Carbone, David P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gandara, David R. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCO precision oncology |d Alexandria, VA : American Society of Clinical Oncology, 2017 |g (2024), 8 vom: Dez., Artikel-ID e2300555, Seite 1-12 |h Online-Ressource |w (DE-627)1067396667 |w (DE-600)2964799-X |w (DE-576)518266486 |x 2473-4284 |7 nnas |a Plasma proteome-based test for first-line treatment selection in metastatic non-small cell lung cancer |
| 773 | 1 | 8 | |g year:2024 |g number:8 |g month:12 |g elocationid:e2300555 |g pages:1-12 |g extent:12 |a Plasma proteome-based test for first-line treatment selection in metastatic non-small cell lung cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1200/PO.23.00555 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/PO.23.00555 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250701 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 138659702 |a Christopoulos, Petros |m 138659702:Christopoulos, Petros |d 50000 |e 50000PC138659702 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1929404174 |e 474093079X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","display":"Christopoulos, Petros","family":"Christopoulos","given":"Petros"},{"role":"aut","display":"Harel, Michal","given":"Michal","family":"Harel"},{"given":"Kimberly","family":"McGregor","role":"aut","display":"McGregor, Kimberly"},{"display":"Brody, Yehuda","role":"aut","family":"Brody","given":"Yehuda"},{"display":"Puzanov, Igor","role":"aut","family":"Puzanov","given":"Igor"},{"given":"Jair","family":"Bar","display":"Bar, Jair","role":"aut"},{"role":"aut","display":"Elon, Yehonatan","family":"Elon","given":"Yehonatan"},{"display":"Sela, Itamar","role":"aut","given":"Itamar","family":"Sela"},{"role":"aut","display":"Yellin, Ben","family":"Yellin","given":"Ben"},{"display":"Lahav, Coren","role":"aut","family":"Lahav","given":"Coren"},{"display":"Raveh, Shani","role":"aut","family":"Raveh","given":"Shani"},{"given":"Anat","family":"Reiner-Benaim","role":"aut","display":"Reiner-Benaim, Anat"},{"given":"Niels","family":"Reinmuth","role":"aut","display":"Reinmuth, Niels"},{"role":"aut","display":"Nechushtan, Hovav","given":"Hovav","family":"Nechushtan"},{"family":"Farrugia","given":"David","role":"aut","display":"Farrugia, David"},{"role":"aut","display":"Bustinza-Linares, Ernesto","given":"Ernesto","family":"Bustinza-Linares"},{"family":"Lou","given":"Yanyan","role":"aut","display":"Lou, Yanyan"},{"family":"Leibowitz","given":"Raya","display":"Leibowitz, Raya","role":"aut"},{"role":"aut","display":"Kamer, Iris","family":"Kamer","given":"Iris"},{"family":"Zer Kuch","given":"Alona","role":"aut","display":"Zer Kuch, Alona"},{"given":"Mor","family":"Moskovitz","role":"aut","display":"Moskovitz, Mor"},{"display":"Levy-Barda, Adva","role":"aut","given":"Adva","family":"Levy-Barda"},{"role":"aut","display":"Koch, Ina","family":"Koch","given":"Ina"},{"family":"Lotem","given":"Michal","role":"aut","display":"Lotem, Michal"},{"family":"Katzenelson","given":"Rivka","display":"Katzenelson, Rivka","role":"aut"},{"role":"aut","display":"Agbarya, Abed","family":"Agbarya","given":"Abed"},{"family":"Price","given":"Gillian","role":"aut","display":"Price, Gillian"},{"display":"Cheley, Helen","role":"aut","given":"Helen","family":"Cheley"},{"role":"aut","display":"Abu-Amna, Mahmoud","given":"Mahmoud","family":"Abu-Amna"},{"given":"Tom","family":"Geldart","role":"aut","display":"Geldart, Tom"},{"given":"Maya","family":"Gottfried","role":"aut","display":"Gottfried, Maya"},{"family":"Tepper","given":"Ella","display":"Tepper, Ella","role":"aut"},{"role":"aut","display":"Polychronis, Andreas","family":"Polychronis","given":"Andreas"},{"given":"Ido","family":"Wolf","role":"aut","display":"Wolf, Ido"},{"display":"Dicker, Adam P.","role":"aut","given":"Adam P.","family":"Dicker"},{"family":"Carbone","given":"David P.","display":"Carbone, David P.","role":"aut"},{"role":"aut","display":"Gandara, David R.","family":"Gandara","given":"David R."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"id":{"eki":["1929404174"],"doi":["10.1200/PO.23.00555"]},"note":["Online veröffentlicht am 21. März 2024","Gesehen am 01.07.2025"],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"December 2024"}],"name":{"displayForm":["Petros Christopoulos, MD, PhD; Michal Harel, PhD; Kimberly McGregor, MD; Yehuda Brody, PhD; Igor Puzanov, MD; Jair Bar, MD, PhD; Yehonatan Elon, PhD; Itamar Sela, PhD; Ben Yellin, PhD; Coren Lahav, MSc; Shani Raveh, PhD; Anat Reiner-Benaim, PhD; Niels Reinmuth, MD; Hovav Nechushtan, MD; David Farrugia, MD; Ernesto Bustinza-Linares, MD; Yanyan Lou, MD; Raya Leibowitz, MD, PhD; Iris Kamer, PhD; Alona Zer Kuch, MD; Mor Moskovitz, MD; Adva Levy-Barda, PhD; Ina Koch, PhD; Michal Lotem, MD; Rivka Katzenelson, MD; Abed Agbarya, MD; Gillian Price, MD; Helen Cheley, RN; Mahmoud Abu-Amna, MD; Tom Geldart, MD; Maya Gottfried, MD; Ella Tepper, MD; Andreas Polychronis, MD; Ido Wolf, MD; Adam P. Dicker, MD, PhD; David P. Carbone, MD; and David R. Gandara, MD"]},"relHost":[{"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"eki":["1067396667"],"issn":["2473-4284"],"zdb":["2964799-X"]},"disp":"Plasma proteome-based test for first-line treatment selection in metastatic non-small cell lung cancerJCO precision oncology","physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["Volume 1 (2017)-"],"title":[{"title_sort":"JCO precision oncology","title":"JCO precision oncology","subtitle":"an American Society of Clinical Oncology journal"}],"part":{"issue":"8","pages":"1-12","year":"2024","text":"(2024), 8 vom: Dez., Artikel-ID e2300555, Seite 1-12","extent":"12"},"note":["Gesehen am 06.07.21"],"titleAlt":[{"title":"JCO PO"}],"origin":[{"publisher":"American Society of Clinical Oncology","dateIssuedDisp":"2017-","dateIssuedKey":"2017","publisherPlace":"Alexandria, VA"}],"recId":"1067396667"}],"physDesc":[{"extent":"12 S.","noteIll":"Illustrationen"}],"recId":"1929404174","title":[{"title_sort":"Plasma proteome-based test for first-line treatment selection in metastatic non-small cell lung cancer","title":"Plasma proteome-based test for first-line treatment selection in metastatic non-small cell lung cancer"}]} | ||
| SRT | |a CHRISTOPOUPLASMAPROT2024 | ||